Unity Biotechnology Inc [NASDAQ: UBX] loss -10.67% on the last trading session, reaching $308400.0 price per share at the time.
Unity Biotechnology Inc represents 17.21 million in outstanding shares, while the company has a total market value of $5.90 million with the latest information. UBX stock price has been found in the range of $0.241 to $0.4148.
If compared to the average trading volume of 308.40K shares, UBX reached a trading volume of 14019439 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Unity Biotechnology Inc [UBX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for UBX shares is $1.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on UBX stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Unity Biotechnology Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 27, 2025. While these analysts kept the previous recommendation, Mizuho dropped their target price from $6 to $1. The new note on the price target was released on May 16, 2025, representing the official price target for Unity Biotechnology Inc stock. Previously, the target price had yet another raise to $8, while Rodman & Renshaw analysts kept a Buy rating on UBX stock. On November 16, 2023, analysts increased their price target for UBX shares from 2 to 4.
Trading performance analysis for UBX stock
Unity Biotechnology Inc [UBX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -57.11. With this latest performance, UBX shares dropped by -50.94% in over the last four-week period, additionally sinking by -66.85% over the last 6 months – not to mention a drop of -64.86% in the past year of trading.
Unity Biotechnology Inc [UBX]: A deeper dive into fundamental analysis
Return on Equity for this stock declined to -61.66%, with Return on Assets sitting at -61.66%.
Unity Biotechnology Inc [UBX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for UBX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Unity Biotechnology Inc go to 40.77%.
An analysis of Institutional ownership at Unity Biotechnology Inc [UBX]
There are presently around $17.19%, or 17.52%% of UBX stock, in the hands of institutional investors.
